Sentien grabs Series A funds from BIVF and Portage Biotech

By Iris Dorbian — 4 months ago

Medford, Massachusetts-based Sentien Biotechnologies Inc, which develops cell-based therapies for acute organ failure, has raised an undisclosed amount of Series A funding. The investors were Boehringer Ingelheim Venture Fund USA Inc and Portage Biotech Inc. In addition to the funding, Dr. Martin Heidecker, a managing director at BIVF and Dr. Greg Bailey, chairman of Portage, have been added to Sentien’s board of directors.


ViraTherapeutics raises $4 mln

By Luisa Beltran — 5 months ago

ViraTherapeutics GmbH said Wednesday it raised 3.6 million euros (US$4 million) in a first close of a Series A financing round. Boehringer Ingelheim Venture Fund and EMBL Ventures co-led the round, while Austria Wirtschaftsservice through its Venture-Capital-Initiative also invested. Innsbruck, Austria-based ViraTherapeutics is biopharmaceutical company developing cancer immunotherapies.


Promethera Biosciences nabs $31.4 Series C

By Iris Dorbian — 1 year ago

Belgium-based Promethera Biosciences, a biotech firm that focuses on treating liver diseases, has closed its Series C round at $31.4 million. The investors included SFPI-FPIM, Vesalius Biocapital, Boehringer Ingelheim Venture Fund and SMS Investments.


Rigontec raises $11.95 mln

By Luisa Beltran — 1 year ago

Rigontec GmbH said Tuesday it raised €9.45 million (US$11.95 million) in a first close of a Series A round co-led by Wellington Partners and Boehringer Ingelheim Venture Fund. Other investors include NRW Bank and High-Tech Gründerfonds. Rigontec, a biopharmaceutical company, is developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.


Eyevensys Receives Investment From Boehringer Ingelheim

By Mark Boslet — 3 years ago

Eyevensys said it received an equity investment from the Boehringer Ingelheim Venture Fund. Further details were not available. The company raised about $2.1 million in its first round of funding in January 2012. It said early investors – Innobio, managed by CDC Entreprises; Inserm Transfert Initiative; and CapDecisif Management – plan to participate in the second round.


ArmaGen Technologies Raises $17m Series A

By Angela Sormani — 3 years ago

ArmaGen Technologies has closed a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics. The lead investor is Boehringer Ingelheim Venture Fund, joined by Shire plc, Takeda Ventures, Inc., and Mitsui & Co. Global Investment, Inc.